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Abstract
Background: Galectins are known to regulate cell differentiation and growth as well as cell adhesion and apoptosis.
Galectins have been discussed as possible prognosticators for survival in renal cell cancer (RCC) and other urological
tumors. They might also play an emerging role as possible new marker-proteins for RCC. In this study, we analyzed the
expression of galectin-1 and galectin-3 mRNA in order to further investigate their clinical significance in RCC.
Methods: Tissue samples were obtained from 106 patients undergoing surgery for RCC. The expression of galectin-1
and galectin-3 mRNA in normal kidney and corresponding cancer tissue was analyzed using quantitative real time
PCR. Differences in expression levels of paired tissue samples were assessed using paired two-sample tests.
Associations of relative mRNA expression levels in tumor tissues with clinical findings were analyzed using univariate
logistic regression.
Results: The expression of galectin-1 (p < 0.001) and -3 (p < 0.001) mRNA were significantly higher in RCC when
compared to the adjacent normal kidney tissue. For clear cell RCC, an association of male gender with higher
galectin-1 and galectin-3 mRNA expression (p = 0.054, p = 0.034) was detected. For all RCCs, galectin-1 mRNA
expression failed to show a significant association with advanced disease as well as a higher rate of lymph node
metastases (p = 0.058, p = 0.059).
Conclusion: The mRNA expression of galectin-1 and galectin-3 is significantly increased in RCC cancer tissue. The
higher mRNA expression in tumor tissue of male patients raises the question of a functional connection between
galectins and the higher prevalence of RCC in men. Associations with advanced disease might lead to new ways of
identifying patients at higher risk of recurrent disease and might even facilitate early metastasectomy with curative
intent.
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Background
RCC accounts for approximately 2–3% of all malignan-
cies in adults with a higher incidence in males. Inci-
dence peaks in the sixth and seventh decade of life [1,2].
A variety of risk factors for RCC, such as obesity and
tobacco exposure, have been proposed in the past [1,3].
The incidence of RCC is increasing, most likely due to
the wide implementation of imaging modalities, such as
ultrasonography and CT-scanning [4]. The clinical course
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of the tumor is not or at least difficult to predict [5].
Decision making on active treatment and surveillance
is therefore difficult, especially in the elderly population
where aggressive surgery might put the patient at an
increased peri-operative risk. Although there are no ran-
domized controlled trials, there is evidence for a benefit of
early and complete metastasectomy in patients with RCC
with regard to an improved overall survival [6]. Given
these difficulties of clinical decision making, there is a
strong need for risk stratification in order to improve early
identification of patients with recurrent disease after cura-
tive treatment. However reliable predictive biomarkers
© 2014 von Klot et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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to adequately assess the hazard of treated and untreated
patients with RCC are currently lacking.
Galectins are proteins of 30 kDa that can be found in
the cellular nucleus, the cytosol and also in the extra-
cellular space. They are members of the lectin family,
a group of β-galactoside binding proteins. Lectins had
previously been shown to be involved in several cellular
functions, such as cell-cell interactions, cell adhesion, pro-
liferation, angiogenesis, inflammation, fibrogenesis and
apoptosis [7-10]. We previously reported on alterations
of galectin expression in prostate and bladder cancer
[11,12] . Out of the currently described 18 galectins, we
focused our research on galectin-1 and -3 because they
both had previously been correlated with the development
of various malignancies [13-15]. Objective of our current
study was the further characterization of galectin-1 and -3
mRNA expression in RCC. Furthermore we were look-
ing for correlations of galectin-1 and -3 mRNA expres-




Tissue from the tumor itself and adjacent correspond-
ing tumor free renal tissue of 106 patients undergo-
ing kidney surgery were collected between 2001 and
2005. Samples were collected at Eberhard Karls Univer-
sity Tuebingen. All tissue samples were obtained during
the operation. Adjacent normal appearing tissues were
sampled ≈0.5-2 cm distant from the margin of the pri-
mary tumor site. All samples were collected immediately
after surgery, snap frozen in liquid nitrogen and stored
at −80°C. Tissue was selected to include at least 75% vital
tumor.
Tumor stages and histological subtypes were assessed
according to the UICC 2002 issue of the TNM system [16]
by two separate pathologists. Grading was based on the
Fuhrman grading system [17] while histological subtypes
were defined in accordance with the consensus classifica-
tion of renal cell neoplasia [18]. All patients were systemic
therapy-naïve and did not receive any neoadjuvant treat-
ment before definitive surgery.
Localized RCC was defined as pT ≤ 2 without lymph
node involvement or the presence of organ-metastasis
and grading ≤ G2, while advanced RCCs were defined
as pT ≥ 3 or lymph node positive or organ metastasis
or > G2.
All data were gathered by data managers and physicians
andmaintained by a relational database. The approval was
granted by the ethics committee (Ethics Committee of the
Medical Faculty, University of Tuebingen - Germany) and
informed consent was obtained from all patients prior to
surgery. Patient’s clinical and histopathological parame-
ters are summarized in Table 1.
Table 1 Histopathological and clinical parameters of
patients with RCC
Patient characteristics All RCC all tumours %
Total 106 100%
Patients




Clear cell 77 72.6%
Papillary 22 20.7%
Chromophobe 5 4.7%


















Visceral metastasis* 23 21.7%
advanced/metastatic disease
(pT3-4 or N+/M+/>G2) 49 46.2%
∗At time of surgical intervention. SD = standard deviation, LN = lymph node,
N+ = lymph node metastasis, M+ = organ metastasis.
Patients
The mean age of all patients was 63.7 years (SD ± 11.8).
The male-female ratio was 68/38 (64.2% / 35.8%).
Histopathological subclassification showed 77 patients
with clear cell RCC, 22 patients with papillary and five
patients with chromophobe tumors; two patients had
non-classified histology.
Primary cells
For an external reference control, renal proximal tubular
epithelial cells (RPTEC; Lonza (Basel, Switzerland) were
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cultured and prepared according to the manufacturers
instructions.
Quantitative real-time PCR analysis
Of each tissue sample two sections were stained with
hematoxylin-eosin and evaluated by a pathologist. Tis-
sue was prepared from 20 cryo sections (each 20 μm).
The total RNA was then extracted using TriReagent
(Ambion). Conversion into single-stranded complemen-
tary DNA (cDNA)was performed using theHigh Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA). For quantitative real time PCR
(qRT-PCR), we used the ABI 7900 Fast Sequence Detec-
tion System with universal PCR master mix and TaqMan
expression assays (Applied Biosystems) according to the
manufacturers instructions. The here used TaqMan assays
were LGALS1 (Assay ID: Hs00355202_m1), LGALS3
(Assay ID: Hs00173587_m1), RPL13A (Hs03043885_g1),
HPRT1 (Hs99999909_m1) and GUSB (Hs00939627_m1).
The human RPL13A, HPRT1 and GUSB transcripts were
used as endogenous controls. For biological control, we
used cDNA from RPTEC primary cell transcripts. In
addition, blank, no-template and no reverse transcrip-
tion controls were included for each measurement. The
method of Livak et al. [19] and reference Ct values
derived from the biological reference RPTEC were used
for calculation of Ct and all relative quantity values.
Data were assessed using the SDS 2.3 Manager, dataAs-
sist V1.0 software. The endogenous controls RPL13A,
HPRT1 and GUSB were combined using the dataAssist
software V1.0 and ”arithmetic mean” as method for nor-
malization. 106 measurements for galectin-1 expression
were successfully performed; for galectin-3 one measure-
ment did not meet the standards and was excluded. All
statistics and graphics were performed using the sta-
tistical programming language R 2.15-2. For graphical
analysis we used assorted differences plots, jitter plots
and bean plots that were generated using R statistical
software [20]. In all statistical tests the two-sided type-
I-error was set to 5%. For statistical analysis of galectin
mRNA expression in tumor vs. paired adjacent tissue, we
used the paired t-test and the Wilcoxon signed-rank test.
For correlation of relative expression levels with recur-
rence free survival we dichotomized our data according to
median, mean as well as stepwise dichotomization anal-
ysis. Kaplan-Meier analysis and Cox regression was then
used to evaluate the influence of mRNA expression pat-
terns on recurrence free survival. Logistic regression was
used to correlate galectin mRNA expression with clinical
parameters.
Results
Paired analysis of tumorous kidney tissue in compar-
ison with adjacent microscopically normal appearing
tissue was performed with 75 samples for galectin-1
and galectin-3 mRNA expression. Patient characteris-
tics are depicted in Table 2. The mRNA expression of
galectin-1 (p < 0.001, Figure 1) and galectin-3 (p < 0.001,
Figure 2) were significantly higher in RCC when com-
pared to the surrounding normal kidney tissue in paired
analysis.
For galectin-1, mean mRNA expression in RCC and
adjacent normal tissue was 1.57 (SD 0.86) and 0.99
(SD 0.62). For galectin-3, mean expression was -0.3
Table 2 Histopathological and clinical parameters of
patients subjected to paired analysis of galectin-1 and
galectin-3 expression in tumors vs. adjacent normal
kidney tissue
Patients for paired analysis No. %
Total 75 100%
Patients

























Visceral metastasis* 19 25.3%
locally advanced/metastatic
disease (pT3>4 and/or N/M+) 36 48%
∗At time of surgical intervention. SD = standard deviation, LN = lymph node,
N+ = lymph node metastasis, M+ = organ metastasis.
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Figure 1 Assorted differences plot for paired analysis: Difference
between relative logarithmic (ln) expressions of galectin-1
mRNA in RCC tissue compared to the surrounding normal
kidney tissue (p < 0.001).
(SD 0.88) and -0.9 (SD 0.53) respectively. Relative
expression levels with regard to sample and tumor charac-
teristics are depicted in Table 3.
For clear cell RCC, logistic regression showed an asso-
ciation of male gender with higher galectin-1 (p = 0.054)
and -3 (p = 0.034) mRNA expression as depicted in
Figure 3 and Figure 4.
These gender differences were seen exclusively in clear
cell RCC tissue and did not occur in the corresponding
normal tissue.
We also compared clinical parameters with the expres-
sion of galectin-1 and galectin-3. Clinical follow up was
available for 43 patients. As could be expected, recur-
rence free survival was associated with advanced disease
Figure 2 Assorted differences plot for paired analysis: Difference
between relative logarithmic (ln) expressions of galectin-3
mRNA in RCC tissuecompared to the surrounding normal kidney
tissue (p < 0.001).
Table 3 Histopathological parameters and relative
expression levels of galectin-1/3 mRNA in all patients with
RCC
Sample/pathology n Mean relative expression SD
(Ct)
LGALS1 106
Male 68 1.58 0.87
Female 38 1.37 0.91
Age (<median) 54 1.50 0.96
Age (≥median) 52 1.48 0.81
M0 83 1.41 0.90
M+ 23 1.77 0.78
N0 95 1.44 0.86
N+ 11 1.97 1.03
Localized RCC* 57 1.34 0.89
Advanced RCC* 49 1.67 0.86
Grade (≤ 2) 89 1.46 0.85
Grade (> 2) 17 1.63 1.09
LGALS3 105
Male 38 -0.41 1.04
Female 67 -0.06 0.79
Age (<median) 54 -0.25 0.97
Age (≥median) 51 -0.12 0.82
M0 82 -0.18 0.90
M+ 23 -0.23 0.92
N0 94 -0.21 0.86
N+ 11 -0.001 1.23
Localized RCC* 56 -0.13 0.91
Advanced RCC* 49 -0.25 0.89
Grade (≤ 2) 88 -1.62 0.9
Grade (> 2) 17 -0.43 0.91
SD = standard deviation, N+ = lymph node metastasis, M+ = organ metastasis.
∗Advanced RCC was defined as pT≥3, N1 and/or M1, or G>2.
(p = 0.01) andmetastases (p = 0.002). However no correla-
tion between galectin-1 (p = 0.11) or galectin-3 expression
(p = 0.214) and RCC recurrence after 75 month could be
demonstrated in univariate analysis.
When dichotomizing our data according to the mean
expression level or in stepwise dichotomization analy-
sis, no differences with regard to recurrence free survival
could be demonstrated in Cox regression or Kaplan Meier
analysis.
There was no association of galectin-1 (p = 0.48) or
galectin-3 (p = 0.45) mRNA expression with tumor grade.
When looking at extend of disease, galectin-1 mRNA
expression for all patients with RCC failed to reach the sig-
nificance level with regard to advanced disease (p = 0.058,
Figure 5) and lymph node metastasis (p = 0.059, Figure 6).
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Figure 3 Jitter plot showing the relative logarithmic (ln)
expression of galectin-1 mRNA in clear cell RCC tissue in male
and female patients (p = 0.054) with the horizontal line
indicating the median expression level.
Discussion
Galectin-1 had previously been shown to be elevated
in a variety of cancers such as head and neck squa-
mous cell carcinoma, thyroid cancer or hepatocellu-
lar carcinoma [13,14,21]. Moreover, the plasma levels
of galectin-1 were shown to be significantly higher in
RCC patients when compared to healthy controls [15].
Galectin-3 had also previously been associated with
several cancer entities, such as small-cell lung cancer,
gastric and colorectal cancer [22-24]. Previous studies
were able to show an up-regulation of galectin-3 in
RCC [25,26].
It is well known that the expression of galectin variants
varies between different organ tissues [27]. Therefore we
took great interest in identifying the relative galectin-1
Figure 4 Jitter plot showing the relative logarithmic (ln)
expression of galectin-3 mRNA in clear cell RCC tissue in male
and female patients (p = 0.034) with the horizontal line
indicating the median expression level.
Figure 5 Bean plot analysis of relative logarithmic (ln) galectin-1
expression in patients with localized vs. advanced disease
(p = 0.058) with the horizontal line indicating the median
expression level.
and galectin-3 mRNA concentration by using tumor and
non-tumor tissue from the same patient as reference. By
doing so, we were able to eliminate any intra individual
variance in distribution of galectin-1 and -3.
In contrast to our findings, previous studies implicated
a possible negative correlation of galectins with regard
to RCC cancer [28]. Albeit, these results were based on
immunohistochemistry of proteins and not on mRNA
expression analysis, they show that the physiological role
of galectins is highly complicated and may vary between
subtypes. Additionally, among the tumor samples of the
aforementioned study a high expression of galectin-3 was
initially noted that vanished with increasing stage and
grade among tumors and therefore showed the reported
results.
Figure 6 Bean plot analysis of relative logarithmic (ln) galectin-1
expression in patients with- and without nodal involvement
(p = 0.059). The horizontal line is indicating the median expression
level.
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In the present study a significantly increased expression
of galectin-1 and galectin-3 mRNA in RCC was shown
when compared to normal adjacent renal tissue.
These findings support the hypothesis that galectin-1
and -3 may play a role in RCC progression or carcino-
genesis. In this study extend of disease and lymph node
involvement did not correlate with galectin-1 or galectin-3
mRNA expression.
Significance levels were narrowly missed. Others could
show a significant correlation of advanced RCC and
metastasis for galectin-3 using real time PCR as well as
immunehistochemistry [29].
Our findings of higher galectin-1 and -3 levels in clear
cell RCC tissue of male patients and the fact that neither
of the two encoding genes is located on the sex chromo-
somes is very interesting since RCC most predominantly
occurs in the male population.
With regard to a possible mechanism of action, pre-
vious data on various tumors suggest that galectin-3
may mediate invasion and the migration of cancer cells
via the Wnt/β-catenin signaling pathway and Akt (Pro-
tein Kinase B) phosphorylation. The proposed model
describes galectin-3 to increase Akt phosphorylation,
thereby increasing phosphorylation and inactivation of
glycogen synthase kinase-3β (GSK-3β). With inactiva-
tion of GSK-3β , the degradation of β-catenin is reduced.
With increased cellular levels, β-Catenin can translo-
cate to the nucleus and activate transcription after
binding to transcription factors [30,31]. Others have
argued that the effect of galectins in the immune T-
cell response plays an important role: Higher levels of
galectin-3 for instance have previously been shown to
induce T-cell apoptosis, thereby providing a potential
immune escape mechanism [32]. The latter findings orig-
inate from animal models, colorectal cancer research
or in vitro studies. The impact of galectin mediated T-
cell supression had not yet been fully shown in RCC
[33,34].
Our findings are not without limitations. One possible
issue in our evaluation might be a possible contamination
of renal cell tissue with lymphocytes. Lymphatic cells are
often predominantly found in or around cancerous tissue.
It has been shown that the expression of galectins is upreg-
ulated in the presence of stimulated B-cells where they
play a putative role in immunemodulation and T-cell con-
trol [35]. Likewise immune mediated activation of T-cells
is known to lead to an increased expression of galectin-1
[36]. In view of our histopathological control sections we
can however exclude higher concentrations of lymphatic
tissue invasion. Therefore the aforementioned confound-
ing effects may not play an important role in this study.
In addition, our data are in accordance with other stud-
ies showing equivalent elevations of galectins in cancerous
tissue [26,29,37,38].
Our data on galectin-1 and -3 encourage further inves-
tigations such as the influence on survival in larger patient
cohorts or the relevance of these proteins with regard
to new therapeutic agents and targeted therapy. Further
studies should also include the role of galectin-1 and -3 on
the protein level as well as sex specific expression.
Conclusion
To our knowledge this is the first study simultaneously
correlating clinical tumor parameters with galectin-1
and -3 using real time PCR and mRNA expression pat-
terns. The here found higher expression of galectin-1 and
galectin-3 inmale patientsmight lead to furthermolecular
and biochemical research with regard to gender specific
differences for the prevalence of RCC. The shown results
regarding with advanced RCCs might lead to new ways of
identifying patients at higher risk of recurrent disease and
might even facilitate early metastasectomy.
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